• 1
    Bang OY, Lee PH, Joo SY, Lee JS, Joo IS, Huh K. Frequency and mechanism of stroke recurrence after cryptogenic stroke. Ann Neurol 2003; 54: 22734.
  • 2
    Sacco RL, Ellemberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25: 38290.
  • 3
    Petty GW, Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes. A population-based study of incidence and risk factor. Stroke 1999; 30: 25136.
  • 4
    Petty GW, Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes. A population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 10628.
  • 5
    Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtype according to TOAST criteria: incidence, recurrence and long-term survival in ischemic stroke subtype: a population-based study. Stroke 2001; 32: 273540.
  • 6
    Hart RG. Stroke prevention in atrial fibrillation. Curr Cardiol Rep. 2000; 2: 515.
  • 7
    Paciaroni M, Agnelli G, Caso V, Venti M, Milia P, Silvestrelli G, Parnetti L, Biagini S. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005; 3: 121823.
  • 8
    Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 23641.
  • 9
    Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, Boonyakarnkul S, Warlow C. Atrial fibrillation and stroke: prevalence in different subtype of stroke and influence on early and long term prognosis (OCSP). BMJ 1992; 305: 14605.
  • 10
    Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke 1995; 26: 152730.
  • 11
    Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. Stroke 1993; 24: 2630.
  • 12
    Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 164751.
  • 13
    Arning C, Schrattenholzer A, Lachenmayer L. Cervical carotid artery vasospasm causing cerebral ischemia. Stroke 1998; 29: 10636.
  • 14
    Amarenco P, Duyckaerts C, Tzourio C, Hénin D, Bousser MG, Hauw JJ. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992; 326: 2215.
  • 15
    Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG. Atherosclerosis disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331: 14749.
  • 16
    Macleod MR, Amarenco P, Davis SM, Donnan GA. Atheroma of the aortic arch: an important and poorly recognised factor in the etiology of stroke. Lancet Neurol 2004; 3: 40814.
  • 17
    Kallikazaros IE, Tsioufis CP, Stefanadis CI, Pitsavos CE, Toutouzas PK. Closed relation between carotid and ascending atherosclerosis in cardiac patients. Circulation 2000; 102: III-2638.
  • 18
    Kitagawa K. Aortogenic embolism is a possible mechanism of cryptogenic stroke. Ann Neurol 2004; 55: 5989.
  • 19
    The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996; 334: 121621.
  • 20
    Rundek T, Di Tullio MR, Sciacca RR, Titova IV, Mohr JP, Homma S, Sacco RL. Association between large aortic arch atheromas and high-intensity transient signals in elderly stroke patients. Stroke 1999; 30: 26836.
  • 21
    Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998; 31: 1348.
  • 22
    Ferrari E, Vidal R, Chevalier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol 1999; 33: 131722.
  • 23
    Tunick PA, Nayar A, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I; NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002; 90: 13205.
  • 24
    Aortic Arch Related Cerebral Hazard Trial website. Accessed 7 February 2007.
  • 25
    Windecker S, Meier B. Patent foramen ovale and septal aneurysm: when and how should they be treated. ACC Curr J Rev 2002; 11: 97101.
  • 26
    Di Tullio M, Sacco RL, Venketasubramanian N, Sherman D, Mohr JP, Homma S. Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients. Stroke 1993; 24: 10204.
  • 27
    Overell JR, Bone I, Less KR. Interatrial septal abnormalities and stroke: a meta-analysis of case control studies. Neurology 2000; 55: 11729.
  • 28
    Meachan RR III, Headley AS, Bronze MS, Lewis JB, Rester MM. Impending paradoxical embolism. Arch Intern Med 1998; 158: 43848.
  • 29
    Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000; 31: 398403.
  • 30
    Falk RH. PFO or UFO? The role of a patent foramen ovale in cryptogenic stroke. Am Heart J 1991; 121: 12646.
  • 31
    Stollemberg C, Slany J, Schuster I, Stöllberger C, Slany J, Schuster I, Leitner H, Winkler WB, Karnik R. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Ann Intern Med 1994; 119: 4615.
  • 32
    Cramer SC, Rondorf G, Maki JH, Kramer LA, Grotta JC, Burgin WS, Hinchey JA, Benesch C, Furie KL, Lutsep HL, Kelly E, Longstreth WT Jr. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke 2004; 35: 4650.
  • 33
    Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, Akkawi NM, Albertini A, Assanelli D, Vignolo LA, Padovani A. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003; 34: 2833.
  • 34
    Hankey GJ, Eikelboom JW, Van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 17939.
  • 35
    Silver MD, Dorsey JS. Aneurysm of the septum primum in the adults. Arch Pathol Lab Med 1978; 102: 625.
  • 36
    Meissner I, Whisnant JP, Khandheira BK, Spittell PC, O’Fallon WM, Pascoe RD, Enriquez-Sarano M, Seward JB, Covalt JL, Sicks JD, Wiebers DO. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc 1999; 74: 8629.
  • 37
    Olivares-Reyes A, Chan S, Lazar EJ, Bandlamudi K, Narla V, Ong K. Atrial septal aneurysm; a new classification in two hundred five adults. J Am Soc Echocardiogr 1997; 10: 64456.
  • 38
    Agmon Y, Khandheria BK, Meissner I, Gentile F, Whisnant JP, Sicks JD, O’Fallon WM, Covalt JL, Wiebers DO, Seward JB. Frequency of atrial septal aneurysm in patients with cerebral ischemic events. Circulation 1999; 99: 19424.
  • 39
    Lynch JJ, Schuchard GH, Gross CM, Wann LS. Prevalence of right-to-left atrial shunting in a healty population: detection by Valsalva maneuver contrast echocardiography. Am J Cardiol 1984; 53: 147880.
  • 40
    Blersch WK, Draganski BM, Holmer SR, Koch HJ, Schlachetzki F, Bogdahn U, Hölscher T. Transcranial duplex sonography in the detection of patient foramen ovale. Radiology 2002; 225: 6939.
  • 41
    Lock JE. Patent foramen ovale is indicated, but the case hasn’t gone to trial. Circulation 2000; 101: 838.
  • 42
    Shuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 2000; 109: 45662.
  • 43
    De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, Beccia M, Colonnese C, Fedele F, Fieschi C, Pandian NG. Morphological and functional characteristics of patent foramen ovale and their embolic embolic implications. Stroke 2000; 31: 240713.
  • 44
    Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. Transcranial Doppler and risk of recurrence in patient with stroke and patent foramen ovale. Eur J Neurol 2003; 10: 12935.
  • 45
    Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T; American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006; 37: 577617.
  • 46
    Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patient with patent foramen ovale : the Lausanne Study. Neurology 1996; 46: 13015.
  • 47
    Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and atrial Septal Aneurysm. Am Heart J 1995; 130: 10838.
  • 48
    Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 262531.
  • 49
    Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 144451.
  • 50
    Dearani JA, Ugurlu BS, Danielson GK, Daly RC, McGregor CG, Mullany CJ, Puga FJ, Orszulak TA, Anderson BJ, Brown RD Jr, Schaff HV. Surgical patent foramen ovale closure for prevention of paradoxical embolism related cerebrovascular ischemic events. Circulation 1999; 100(Suppl. 19): II1715.
  • 51
    Anzai H, Child J, Natterson B, Krivokapich J, Fishbein MC, Chan VK, Tobis JM. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004; 93: 42631.
  • 52
    Khairy P, O’Donnel CP, Landzberg MJ, et al. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboembolism: a systematic review. Ann Intern Med 2003; 139: 75360.
  • 53
    Windecker S, Whal A, Nedeltchev K. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004; 44: 7508.
  • 54
    Bruch L, Parsi A, Grad MO, Rux S, Burmeister T, Krebs H, Kleber FX. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation 2002; 105: 28458.
  • 55
    Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolitic therapy for ischemic stroke: the seventh ACCP Conference on Antithrombotic and Thrombolitic Therapy. Chest 2004; 126(Suppl.): 483S512S.